637 related articles for article (PubMed ID: 30471402)
21. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
Takemura M; Wise MG; Hackel MA; Sahm DF; Yamano Y
J Antimicrob Chemother; 2023 Aug; 78(8):2019-2027. PubMed ID: 37390312
[TBL] [Abstract][Full Text] [Related]
22. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):321-325. PubMed ID: 31029489
[TBL] [Abstract][Full Text] [Related]
23. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.
Ito A; Kohira N; Bouchillon SK; West J; Rittenhouse S; Sader HS; Rhomberg PR; Jones RN; Yoshizawa H; Nakamura R; Tsuji M; Yamano Y
J Antimicrob Chemother; 2016 Mar; 71(3):670-7. PubMed ID: 26645269
[TBL] [Abstract][Full Text] [Related]
24. Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM; Rizk JG
Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
[TBL] [Abstract][Full Text] [Related]
25. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).
Gales AC; Jones RN; Sader HS
Clin Microbiol Infect; 2006 Apr; 12(4):315-21. PubMed ID: 16524407
[TBL] [Abstract][Full Text] [Related]
26. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
Cercenado E; Cardenoso L; Penin R; Longshaw C; Henriksen AS; Pascual A
J Glob Antimicrob Resist; 2021 Sep; 26():292-300. PubMed ID: 34274538
[TBL] [Abstract][Full Text] [Related]
28. Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible
Burnard D; Robertson G; Henderson A; Falconer C; Bauer MJ; Cottrell K; Gassiep I; Norton R; Paterson DL; Harris PNA
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168603
[TBL] [Abstract][Full Text] [Related]
29. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Simner PJ; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
[TBL] [Abstract][Full Text] [Related]
30. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
31. In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates.
Jacquier H; Le Monnier A; Carbonnelle E; Corvec S; Illiaquer M; Bille E; Zahar JR; Jauréguy F; Fihman V; Tankovic J; Cattoir V;
Microb Drug Resist; 2012 Aug; 18(4):396-401. PubMed ID: 22335615
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany.
Kresken M; Korte-Berwanger M; Gatermann SG; Pfeifer Y; Pfennigwerth N; Seifert H; Werner G
Int J Antimicrob Agents; 2020 Oct; 56(4):106128. PubMed ID: 32758648
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates.
Khanchandani H; Chaudhury M; Rao MS; Ramakrishna N; Venkataramana B; Chaudhury A
Indian J Med Microbiol; 2024; 48():100556. PubMed ID: 38447857
[TBL] [Abstract][Full Text] [Related]
34. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
35. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
Aoki T; Yoshizawa H; Yamawaki K; Yokoo K; Sato J; Hisakawa S; Hasegawa Y; Kusano H; Sano M; Sugimoto H; Nishitani Y; Sato T; Tsuji M; Nakamura R; Nishikawa T; Yamano Y
Eur J Med Chem; 2018 Jul; 155():847-868. PubMed ID: 29960205
[TBL] [Abstract][Full Text] [Related]
36.
Wise MG; Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
Microb Drug Resist; 2023 Aug; 29(8):360-370. PubMed ID: 37253158
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.
Jones RN; Pfaller MA; Marshall SA; Hollis RJ; Wilke WW
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):187-92. PubMed ID: 9401811
[TBL] [Abstract][Full Text] [Related]
38.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
39. Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.
Huband MD; Ito A; Tsuji M; Sader HS; Fedler KA; Flamm RK
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):198-200. PubMed ID: 28410852
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
